Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD
Status:
Completed
Trial end date:
2021-06-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether bromodomain extraterminal domain (BET)
inhibition treatment with RVX000222 in high-risk type 2 diabetes mellitus patients with
coronary artery disease increases the time to major adverse cardiovascular events.